Anakinra;Anakinra (IL-1Ra);Recombinant human interleukin-1 receptor antagonist,rhIL-1ra;Anakinra, Kineret, Recombinant Human Interleukin1 receptor antagonist, rhIL-1Ra;Anakinra, Interleukin1 receptor antagonist, IL-1ra, Kineret;Anakinra, Kineret, Recombinant Human Interleukin1 receptor antagonist;Interleukin1 receptor antagonist, IL-1ra, Anakinra, Kineret;Kineret
SMILES
Anakinra
用途
Treatment of rheumatoid arthritis (RA); treatment of cryopyrin-associated periodic syndromes (CAPS); treatment of neonatal-onset multisystem inflammatory disease (NOMID); treatment of adult-onset Still’s disease; management of recurrent gout in patients who have failed allopurinol therapy; first-line therapy for systemic juvenile idiopathic arthritis (sJIA) due to the pivotal role of IL-1 in its pathogenesis; inhibition of IL-1-mediated inflammatory responses to reduce tissue damage caused by immune responses, infections, or inflammation; used subcutaneously in children at a dose of 1–2 mg/(kg·day), with a maximum dose of 100 mg/day.